

Minnesota Board of Pharmacy

EIGHT HUNDRED AND TWENTY FOURTH MEETING

At approximately 9:00 a.m., on October 31, 2012, the Minnesota Board of Pharmacy met in Conference Room A, at the University Park Plaza Building, 2829 University Avenue Southeast, Minneapolis, Minnesota, for the purpose of conducting a general business meeting. All members of the Board were in attendance. Also in attendance were the Board's Executive Director, Dr. Cody Wiberg, Board's Legal Counsel, Mr. Bryan Huffman, and Board of Pharmacy staff, Ms. Candice Fleming, Mr. Leslie Kotek, Ms. Karen Schreiner, Mr. Steven Huff, Mr. Timothy Litsey, and Ms. Patricia Eggers. The Board's President, Mr. James Koppen, called the meeting to order.

The Board then went into a closed session.

At the conclusion of the closed session, the meeting was reopened to the public.

The Board then discussed the minutes of the September 19, 2012 business meeting. Mr. Bob Goetz moved and Ms. Laura Schwartzwald seconded that the minutes be approved as amended. The motion passed.

Mr. Stuart Williams moved and Ms. Karen Bergrud seconded to approve the items on the Consent Agenda and to approve the Consent Agenda. The motion passed. The Consent Agenda for this meeting is as follows:

- Variances
 - Variance Committee Report: approve, as amended by removal of variances from Omnicare.

Ms. Laura Schwartzwald added a presentation from a University of Minnesota student to the remaining agenda.

The Board next received a presentation from Ms. Mary Olympia of the Health Professionals Services Program. Board action was not required at this time.

The Board next discussed the variances that the Variance and Policy Review Committee deferred to the full Board.

- ◆ Omnicel I
 - Approval of Omnicell Generation G4 and Generation G3 Platforms for use as automated drug distribution systems (ADDS)

Present at the meeting were Mr. Daniel Sanchez and Mr. David Krasno. Mr. Krasno and Mr. Sanchez gave a presentation to the Board and answered questions

from the Board. After some discussion, Mr. Stuart Williams moved and Ms. Karen Bergrud seconded that the Omnicell Generation G3 and Generation G4 Platforms be approved for emergency first doses, missed doses and profiled scheduled doses. The motion passed.

- ◆ Talyst/Omnicare
 - Approval of Talyst InSite 300 for use as an automated drug distribution system (ADDS)

Present at the meeting were Ms. Darla Mattson, PIC at Omnicare; Mr. Neal Uitto, Director of Operations at Omnicare; Deb House, General Manager of Omnicare; Mr. Matt Sneller of Talyst, and Mr. Howard Juni, Special Projects at Omnicare. They gave a presentation and answered questions from the Board. After some discussion, Ms. Laura Schwartzwald moved and Mr. Stuart Williams seconded that the Talyst InSite 300 be approved. The motion passed.

- Approval of Omnicare's use of the Talyst InSite 300

Board of Pharmacy members and staff asked questions of the employees of Omnicare. Mr. Jeff Lindoo of Thrifty White Drug made statements regarding discontinuance of medications. It was a consensus of the Board that the policies be deferred until the next Variance and Policy Review Committee meeting and that Omnicare work with the Board Surveyors regarding concerns that the Board Surveyors have regarding the policies and procedures.

At this time Dr. Cody Wiberg presented the following sections of statutes that need consideration for legislative action during the 2013 session of the Legislature.

- 151.01 Definitions
- 151.37 Legend Drugs, Who May Prescribe, Possess
- 151.47 Wholesale Drug Distributor Licensing Requirements
- 151.361 Manufacturer Disclosure
- 152.126 Controlled Substances Prescription Electronic Reporting System
- 148.235 Prescribing Drugs and Therapeutic Devices
- 151.26 Exceptions

Several comments were made for additions to the changes. It was the consensus of the Board deemed that Dr. Wiberg should proceed with the work necessary to make the statutory changes.

Next, Ms. Batool Dawood gave a presentation on a research project that she completed concerning potential barriers to counseling. The Board thanked her for her presentation, but decided that no immediate action was required.

Next Dr. Cody Wiberg, Mr. Stuart Williams, and Mr. Bob Goetz tabled their presentation on their attendance at the Tri-Regulator Symposium until the next meeting. No Board action was required at this time.

Dr. Wiberg next gave an update on the Prescription Monitoring Program. No Board action was required at this time.

Dr. Wiberg next presented the Board with the Surveyor Reports and Pharmacist Licensure Report. No action was required.

There being no further business requiring action by the Board, Mr. Stuart Williams moved to adjourn the meeting. The motion occurred at approximately 1:45 pm. Mr. Bob Goetz seconded the motion. The motion passed.

PRESIDENT

EXECUTIVE DIRECTOR